Provided by Business Wire
Fort Bend Womenâs Center Receives $236,500 for Housing
CommunityBank of Texas and FHLB Dallas Provide Funds for Longer-Term Solution
CommunityBank of Texas, N.A. and the Federal Home Loan Bank of Dallas (FHLB Dallas) have awarded a $236,500 Affordable Housing Program (AHP) subsidy to Fort Bend Womenâs Center (FBWC) for a $3.8 million expansion of its longer-stay housing community.
FBWC helps survivors of domestic violence and sexual assault and their children find safety and self-sufficiency. It operates the only crisis hotline and emergency shelter for survivors of domestic violence and sexual assault in Fort Bend County, Texas.
Bumble raises its initial public offering range to between $37 and $39 a share as well as its offering size, putting it on track to raise as much as $1.8 billion.
(Bloomberg) Bumble Inc., the dating app where women make the first move, is targeting to raise as much as $1.8 billion from its U.S. initial public offering after boosting the size of the deal.The company plans to sell 45 million shares for $37 to $39 apiece, it said in a filing Monday with the U.S. Securities and Exchange Commission. Bumble previously indicated it would look to sell 34.5 million shares at $28 to $30.At the top of the new range, the IPO would value Bumble at about $8 billion, based on the outstanding Class A shares detailed in its listing document. Private equity firm the Blackstone Group Inc. took a majority stake in Bumble’s parent company in 2019, in a transaction that valued it at $3 billion.Austin, Texas-based Bumble was founded in 2014 by Chief Executive Officer Whitney Wolfe Herd. It plans for its shares to begin trading on Feb. 11, the Thursday before Valentine’s Day, Bloomberg News has previously reported.The offering is being led by Goldman Sa
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
Erytech Pharma S.A.February 8, 2021 GMT ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021
No safety issues identified, consistent with observations in previous IDMC reviews
Lyon (France) and Cambridge, MA (U.S.), February 8, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that TRYbeCA-1, a Phase 3 clinical trial evaluating eryaspase in second-line pancrea
05 FEBRUARY 2021 Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the pricing of its upsized initial public offering in the United States of 9,935,896 American Depositary Shares ( ADSs ) representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. All ADSs sold in the offering were offered by Immunocore. The ADSs are expected to begin trading on The Nasdaq Global Select Market on February 5, 2021 under the ticker symbol IMCR. In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional 1,490,384 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering